Clinical trial

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

NCT00310232

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2001-02-01

PhasePHASE3

Study timeline

Study start (unknown)2001-02-01Date precision: month

Registry last updated2024-04-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small-Cell Lung Carcinomaunresolved

Lung Cancerunresolved

Anemiaunresolved

Interventions

Epoetin AlfaDRUG · verified · RxNorm: epoetin alfa

Sponsors & collaborators

Ontario Clinical Oncology Group (OCOG)lead sponsor

Ortho Biotech, Inc.collaborator

Mapped research locations

TorontoOntario, Canada3 MontrealQuebec, Canada1 EdmontonAlberta, Canada1 LondonOntario, Canada1 CalgaryAlberta, Canada1 HamiltonOntario, Canada1 WinnipegManitoba, Canada1 HalifaxNova Scotia, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00310232 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.